Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

NASDAQ: SNDX
$ 11.54 -0.15 (1.28%)
Day High: 11.79
Day Low:  11.39
Volume:    18,479
1:10 PM ET
09.21.17

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations

09.06.17 / 9:00 AM ET